NBIX vs TTGT · P/E 45, rev $1.77B vs rev $486.8M
Neurocrine Biosciences Inc (NBIX) versus TechTarget, Inc. Common Stock (TTGT) — a side-by-side from cached financials, not a winner call.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
TechTarget, Inc. Common Stock (TTGT) is a information technology services company listed on US.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Latest reported TTGT revenue for 2025-12-31 was $486.8M. Net income was -$1.01B. Revenue was up 384.9% from 2024-12-31 to 2025-12-31. TTGT currently screens at market cap $494.7M.
NBIX currently screens at market cap $13.21B and trailing P/E 45.2. TTGT currently screens at market cap $494.7M.
Not investment advice. Open the NBIX and TTGT stock pages for the full models.
Not investment advice.